Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-7117 (Dersimelagon) in Erythropoietic Protoporphyria and X-Linked Protoporphyria
NCT04402489Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Change From Baseline in Average Daily Sunlight Exposure Time to First Prodromal Symptom Associated With Sunlight Exposure at 26 weeks. Started Jun 2020; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT04402489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402489.